<DOC>
	<DOCNO>NCT01126736</DOCNO>
	<brief_summary>The purpose study determine whether Eribulin Mesylate Administered Combination Pemetrexed safe tolerable gain preliminary indication clinical benefit administer Patients Stage IIIB IV Nonsquamous Non Small Cell Lung Cancer .</brief_summary>
	<brief_title>Eribulin Mesylate Administered Combination With Pemetrexed Versus Pemetrexed Alone Second Line Therapy Patients With Stage IIIB IV Nonsquamous Non Small Cell Lung Cancer</brief_title>
	<detailed_description>This open-label , multicenter , randomize study consist Phase Ib portion : safety run-in period 3 ascending dos eribulin ; Phase II portion : randomize 3-arm design . . Phase Ib-Patients recruited cohort , one two parallel arm evaluate different eribulin dose schedule ( Arm 1 : eribulin Day 1 ; Arm 2 : eribulin Days 1 8 ) , minimum 3 maximum 6 patient per cohort . All patient receive pemetrexed ( 500 mg/m2 ) combination eribulin . All patient cohort receive dose level eribulin intra-patient dose escalation . The dose level eribulin escalate additional cohort two arm unless great equal 2 dose limit toxicity ( DLTs ) report low dose level ( ) prior enrollment next dose level . Phase II- Patients randomize 1:1:1 ratio receive either eribulin combination pemetrexed , two dosing schedule ( Arms 1 2 ) , pemetrexed alone ( Arm 3 ) . For Phase Ib II portion , 1 cycle therapy last 21 day , estimate number 6 cycle . Radiologic examination include compute tomography ( CT ) scan chest , abdomen , pelvis appropriate ( CT magnetic resonance image [ MRI ] appropriate ) , perform Screening thereafter every 2 cycle disease progression .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients may enter study meet follow criterion : 1 . Male female patient great equal 18 year age ; 2 . Histologically cytologically confirm nonsquamous NSCLC stage IIIB malignant pleural effusion stage IV disease amenable curative therapy . Patients history stage III disease relapse chemo radiotherapy also eligible ; 3 . Have least 1 site measurable disease Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST ) criteria ; 4 . Have fail 1 prior platinumdoublet contain chemotherapy regimen stage IIIB malignant pleural effusion stage IV nonsquamous NSCLC . One additional cytotoxic regimen allow neoadjuvant , adjuvant , neoadjuvant plus adjuvant therapy Phase II patient . For patient enrolled Phase Ib portion , maximum three total prior regimen allow . Definition Chemotherapy Regimen : Any platinumdoublet contain chemotherapy , may also include biological targeted agent , and/or humanized antibody , give concomitantly , sequentially , , consider 1 regimen . If , due toxicity , dose 1 component must reduce , 1 component regimen must omit , 1 component must replace another similar drug , change version original regimen consider new regimen . However , new component , dissimilar original component , add regimen , new combination consider new regimen . If treatment interrupt surgery radiotherapy , continue unchanged schedule component , treatment consider one regimen despite interruption . 5 . Life expectancy great 3 month ; 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) less 1 ; 7 . Patients must adequate renal function evidence calculated creatinine clearance great 45 mL/min per Cockcroft Gault formula ; 8 . Patients receive daily treatment nonsteroidal antiinflammatory agent ( NSAIDS ) eligible . Patients creatinine clearance 4579 ml/min must able interrupt NSAIDS 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration pemetrexed ; 9 . Patients must adequate bone marrow function evidence absolute neutrophil count ( ANC ) great 1.5 x 10^9/L , hemoglobin great 9.0 g/dL ( hemoglobin le 9.0 g/dL Screening acceptable correct great 9 g/dL growth factor transfusion prior first dose ) , platelet count great 100 x 10^9/L ; 10 . Patients must adequate liver function evidence bilirubin less 1.5 time upper limit normal range ( ULN ) , alkaline phosphatase , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 3 x ULN ( case liver metastasis , less 5 x ULN ) . If bone metastasis , liverspecific alkaline phosphatase may separate total use ass liver function instead total alkaline phosphatase ; 11 . Male female patient childproducing potential must agree use double barrier contraception , oral contraceptive , avoidance pregnancy measure study 90 day last day treatment ; 12 . Females childbearing potential must negative serum pregnancy test ; 13 . Females may breastfeed ; 14 . Ability understand willingness sign write informed consent . Patients may enter study meet follow criterion : 1 . Prior treatment pemetrexed , epothilone , ixabepilone , patupilone , halichondrin B halichondrin Blike compound ; 2 . Received chemotherapy , target therapy , radiotherapy , surgery , immunotherapy within 30 day prior commence study treatment recover treatmentrelated toxicity Grade le 1 , except alopecia ; 3 . History malignancy except : ( 1 ) adequately treat basal squamous cell carcinoma skin ; ( 2 ) curatively treat , ) situ carcinoma uterine cervix , b ) prostate cancer , c ) superficial bladder cancer ; ( 3 ) curatively treat solid tumor evidence disease great 5 year ; 4 . Presence brain metastasis , unless patient received adequate treatment least 4 week prior randomization , stable , asymptomatic , steroid least 4 week prior randomization ; 5 . Received treatment another clinical study within 30 day prior commence study treatment patient recover side effect investigational drug Grade le 1 , except alopecia ; 6 . Are currently receive treatment , include palliative radiotherapy tumor aside control symptom ; 7 . Common Toxicity Criteria ( CTC ) great Grade 3 peripheral neuropathy ; 8 . Require therapeutic dos vitamin K antagonist ; 9 . Uncontrolled pleural effusion , ascites , third space fluid collection ; 10 . Uncontrolled diabetes mellitus Type 1 2 ; Significant cardiovascular impairment ( history congestive heart failure great New York Heart Association ( NYHA ) Grade II , unstable angina myocardial infarction within past 6 month , serious cardiac arrhythmia ) ; 11 . Patients organ allograft require immunosuppression ; 12 . Known positive human immunodeficiency virus ( HIV ) , know hepatitis B surface antigen , hepatitis C positive ; 13 . Hypersensitivity halichondrin B and/or halichondrin B chemical derivative ; Have medical condition would interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>neoplams</keyword>
	<keyword>lung neoplasm</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>IV Nonsquamous Non Small Cell Lung Cancer</keyword>
</DOC>